menu search

PEN / Penumbra, Inc. (PEN) CEO Adam Elsesser on Q2 2022 Results - Earnings Call Transcript

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q2 2022 Results - Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris - Head of Investor Relations Adam Elsesser - President and Chief Executive Officer Sandra Lesenfants - President, Interventional Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President, Strategy Conference Call Participants Lei Huang - Wells Fargo & Company Pito Chickering - Deutsche Bank David Rescott - Truist Securities Mike Matson - Needham & Company Brandon Vazquez - William Blair & Company Operator Good afternoon. My name is Angela, and I will be the conference operator today. Read More
Posted: Aug 7 2022, 09:51
Author Name: Seeking Alpha
Views: 111662

PEN News  

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

By Zacks Investment Research
November 3, 2023

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends. more_horizontal

Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript

Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript more_horizontal

Penumbra: Appeal Improves, Just Not Appealing Yet

By Seeking Alpha
October 16, 2023

Penumbra: Appeal Improves, Just Not Appealing Yet

Penumbra's shares have nearly been cut in half after doubling in a six-month period, making investors cautious. The company has shown continued growth more_horizontal

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

By Zacks Investment Research
October 12, 2023

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses. more_horizontal

Bull of the Day: Penumbra (PEN)

By Zacks Investment Research
September 22, 2023

Bull of the Day: Penumbra (PEN)

Penumbra ( PEN ) is the $10 billion innovator of neurovascular treatments for stroke using catheter aspiration technologies. After a solid beat-and-ra more_horizontal

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

By Zacks Investment Research
September 5, 2023

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank. more_horizontal

Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised

By Zacks Investment Research
August 2, 2023

Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised

Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the seco more_horizontal

Penumbra, Inc. (PEN) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 1, 2023

Penumbra, Inc. (PEN) Q2 2023 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Jee Hamlyn-Harris - IR Adam Elsesser - Chai more_horizontal


Search within

Pages Search Results: